Healthcare
Pacific Biosciences of California, Inc.(PACB)
Live Price
Offline$1.35
+2.27% today
1Y Change
+4.65%
Window
Jun 26, 2025 β Jun 16, 2026
- Market Cap
- $480.00M
- Revenue Growth
- +3.9%
- EPS Growth
- -61.1%
- Dividend Yield
- 0.0%
Coverage: 244 bars Β· Jun 26, 2025 β Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pacific Biosciences of California, Inc. (PACB) is a Healthcare stock with a market cap of $480.00M and listed on NASDAQ. The stock last traded around $1.35 and up 4.7% across the available one-year price window (Jun 26, 2025 β Jun 16, 2026). Baseline metrics include revenue growth of +3.9%, EPS growth of -61.1%, a dividend yield of 0.0%. What stands out right now is revenue +3.9%, EPS -61.1%, free cash flow +46.3% with operating margin -346.1% and ROIC -75.9%. Valuation is more restrained than many high-expectation growth names at price/sales 3.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PACB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+3.9% vs +7.6% peer median
Operating Margin
Below sector median
-346.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report landed above expectations
Q2 2026 was reported on May 7, 2026 with an EPS surprise of +7.7%.
The operating picture looks softer than before
Revenue is at +3.9% and EPS is at -61.1%, with operating margin around -346.1%.
The next real check-in already has a date
The next earnings event is scheduled for Aug 2, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 2 reported quarters, the stock averaged -19.6% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 May 7, 2026 | +7.7% | -14.5% | -26.7% | -12.1% |
Q1 2026 Feb 12, 2026 | +7.7% | -7.1% | -12.5% | -27.7% |
Benchmark Edge
PACB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
PACB
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
PACB Max Drawdown
-58.05%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PACB and SPY.
Company Overview
Pacific Biosciences of California, Inc.
NASDAQ Global Select
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- Leadership
- Christian O. Henry
- IPO Date
- Oct 27, 2010
- Employees
- 575
- Street Address
- 1305 OβBrien Drive
- Mailing
- Menlo Park, CA, 94025
- Region
- Menlo Park, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 521 8000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 3.0
- Price/Book
- 90.3
Growth
- Revenue
- +3.9%
- EPS
- -61.1%
- Free Cash Flow
- +46.3%
Profitability
- Gross Margin
- 28.2%
- Operating Margin
- -346.1%
- Net Margin
- -341.5%
- ROE
- -1123.3%
- ROIC
- -75.9%
Balance Sheet
- Debt/Equity
- 141.98
- Current Ratio
- 6.89
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.